PMID- 35685530
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 2022
DP  - 2022
TI  - The Impact of Telemonitoring on Improving Glycemic and Metabolic Control in 
      Previously Lost-to-Follow-Up Patients with Type 2 Diabetes Mellitus: A 
      Single-Center Interventional Study in the United Arab Emirates.
PG  - 6286574
LID - 10.1155/2022/6286574 [doi]
LID - 6286574
AB  - BACKGROUND: Telemonitoring (TM), mobile-phone technology for health, and 
      bluetooth-enabled self-monitoring devices represent innovative solutions for 
      proper glycemic control, compliance and monitoring, and access to providers. 
      OBJECTIVE: In this study, we evaluated the impact of TM devices on glycemic 
      control and the compliance of 38 previously lost-to-follow-up (LTFU) patients 
      with type 2 diabetes mellitus (T2DM). METHODS: This was an interventional 
      single-center study that randomly recruited LTFU patients from the Dubai Diabetes 
      Center (DDC), UAE. After contact and recruitment by phone, patients had an 
      initial visit at which they were provided with home-based TM devices. A follow-up 
      visit was conducted three months later. RESULTS: The mean HbA1c decreased 
      significantly from 10.3 +/- 1.9% at baseline to 7.4 +/- 1.5% at the end of follow-up, 
      with a mean difference (MD) of -2.9% [95% CI: -3.6 to -2.2]. The percentage of 
      patients with HbA1c <7% was 50% after three months. Home-based blood sugar 
      monitor devices showed a significant reduction in fasting blood glucose (FBG) 
      after three months (MD = -40.1 mg/dL, 95% CI: -70.8 to -9.3). A significant 
      reduction was observed in terms of body weight after three months (MD = -1.3 kg, 
      95% CI: -2.5 to -0.08). The mean number of days the participants used a device 
      was the highest for portable pill dispensers (86.5 +/- 22.8 days), followed by a 
      OneTouch(R) blood glucose monitor (72.9 +/- 23.5 days). CONCLUSIONS: TM led to 
      significant improvements in overall diabetes outcomes, including glycemic control 
      and body weight, indicating its effectiveness in a challenging population of T2DM 
      patients who had previously been lost to follow-up.
CI  - Copyright (c) 2022 Muhammad Hamed Farooqi et al.
FAU - Farooqi, Muhammad Hamed
AU  - Farooqi MH
AUID- ORCID: 0000-0001-6489-3715
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Abdelmannan, Dima Kamal
AU  - Abdelmannan DK
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Al Buflasa, Manal Mubarak
AU  - Al Buflasa MM
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Abbas Hamed, Moataz Abdalla
AU  - Abbas Hamed MA
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Xavier, Maxon
AU  - Xavier M
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Santos Cadiz, Tessa Joyce
AU  - Santos Cadiz TJ
AD  - Dubai Diabetes Center, Dubai Health Authority, Dubai, UAE.
FAU - Nawaz, Faisal Amir
AU  - Nawaz FA
AD  - Cognitive Healthcare International, Dubai, UAE.
LA  - eng
PT  - Journal Article
DEP - 20220420
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - *Blood Glucose/metabolism
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - United Arab Emirates
PMC - PMC9159213
COIS- Faisal Amir Nawaz is the CEO of Cognitive Healthcare International. Other authors 
      have no conflicts of interest to disclose.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/04/20
CRDT- 2022/06/10 02:32
PHST- 2021/10/24 00:00 [received]
PHST- 2022/01/28 00:00 [revised]
PHST- 2022/03/24 00:00 [accepted]
PHST- 2022/06/10 02:32 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/04/20 00:00 [pmc-release]
AID - 10.1155/2022/6286574 [doi]
PST - epublish
SO  - Int J Clin Pract. 2022 Apr 20;2022:6286574. doi: 10.1155/2022/6286574. 
      eCollection 2022.